Ischemic optic neuropathy is one of the major causes of impaired vision or blindness. The incidence of non-arteritic ischemic optic neuropathy ranges between 2.3–10.3 per 100,000 population per year. RPh201 is a botanical extract of gum mastic and is used for the treatment of various neurological diseases. It induces effects like synaptogenesis, immune-modulation, and neuroprotective and neuronal differentiation in vitro and in vivo. The present study evaluates the efficacy and safety of RPh201 for the treatment of ischemic optic neuropathy.
This week's “MEDFACT” discusses a randomized trial from Neuro-Opthalmology, “Phase 2, Randomized, Triple-Masked Trial of RPh201 For Ischemic Optic Neuropathy”. Authors : Eitan Z. Rath et al. Study brief: Objective To asses change in visual acuity and visual field due to RPh201. Number of participants 22 Study type Interventional Study phase Phase…
